Literature DB >> 22366409

The importance of applying a sentinel lymph node mapping algorithm in endometrial cancer staging: beyond removal of blue nodes.

Joyce N Barlin1, Fady Khoury-Collado, Christine H Kim, Mario M Leitao, Dennis S Chi, Yukio Sonoda, Kaled Alektiar, Deborah F DeLair, Richard R Barakat, Nadeem R Abu-Rustum.   

Abstract

OBJECTIVE: To determine the false-negative rate of a surgical sentinel lymph node (SLN) mapping algorithm that incorporates more than just removing SLNs in detecting metastatic endometrial cancer.
METHODS: A prospective database of all patients who underwent lymphatic mapping for endometrial cancer was reviewed. Cervical injection of blue dye was used in all cases. The surgical algorithm is as follows: 1) peritoneal and serosal evaluation and washings; 2) retroperitoneal evaluation including excision of all mapped SLNs and suspicious nodes regardless of mapping; and 3) if there is no mapping on a hemi-pelvis, a side-specific pelvic, common iliac, and interiliac lymph node dissection (LND) is performed. Paraaortic LND is performed at the attendings' discretion. The algorithm was retrospectively applied.
RESULTS: From 9/2005 to 4/2011, 498 patients received a blue dye cervical injection for SLN mapping. At least one LN was removed in 95% of cases (474/498); at least one SLN was identified in 81% (401/498). SLN correctly diagnosed 40/47 patients with nodal metastases who had at least one SLN mapped, resulting in a 15% false-negative rate. After applying the algorithm, the false-negative rate dropped to 2%. Only one patient, whose LN spread would not have been caught by the algorithm, had an isolated positive right paraaortic LN with a negative ipsilateral SLN and pelvic LND.
CONCLUSIONS: Satisfactory SLN mapping in endometrial cancer requires adherence to a surgical SLN algorithm and goes beyond just the removal of blue SLNs. Removal of any suspicious node along with side-specific lymphadenectomy for failed mapping are an integral part of this algorithm. Further validation of the false-negative rate of this algorithm is necessary.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22366409     DOI: 10.1016/j.ygyno.2012.02.021

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  88 in total

Review 1.  Sentinel lymph node in endometrial cancer: a review.

Authors:  Cyril Touboul; Enrica Bentivegna; Catherine Uzan; Sebastien Gouy; Patricia Pautier; Catherine Lhommé; Pierre Duvillard; Christine Haie-Meder; Philippe Morice
Journal:  Curr Oncol Rep       Date:  2013-12       Impact factor: 5.075

2.  Three Lymphadenectomy Strategies in Low-Risk Endometrial Carcinoma: A Cost-Effectiveness Analysis.

Authors:  Rudy S Suidan; Charlotte C Sun; Scott B Cantor; Andrea Mariani; Pamela T Soliman; Shannon N Westin; Karen H Lu; Sharon H Giordano; Larissa A Meyer
Journal:  Obstet Gynecol       Date:  2018-07       Impact factor: 7.661

3.  Impact of Obesity on Sentinel Lymph Node Mapping in Patients with Newly Diagnosed Uterine Cancer Undergoing Robotic Surgery.

Authors:  Ane Gerda Zahl Eriksson; Margaret Montovano; Anna Beavis; Robert A Soslow; Qin Zhou; Nadeem R Abu-Rustum; Ginger J Gardner; Oliver Zivanovic; Richard R Barakat; Carol L Brown; Douglas A Levine; Yukio Sonoda; Mario M Leitao; Elizabeth L Jewell
Journal:  Ann Surg Oncol       Date:  2016-02-23       Impact factor: 5.344

4.  Redefining stage I endometrial cancer: incorporating histology, a binary grading system, myometrial invasion, and lymph node assessment.

Authors:  Joyce N Barlin; Robert A Soslow; Megan Lutz; Qin C Zhou; Caryn M St Clair; Mario M Leitao; Alexia Iasonos; Martee L Hensley; Richard R Barakat; Xavier Matias-Guiu; Nadeem R Abu-Rustum
Journal:  Int J Gynecol Cancer       Date:  2013-11       Impact factor: 3.437

Review 5.  Surgical staging in endometrial cancer.

Authors:  Maria Luisa Gasparri; Donatella Caserta; Pierluigi Benedetti Panici; Andrea Papadia; Michael D Mueller
Journal:  J Cancer Res Clin Oncol       Date:  2018-11-20       Impact factor: 4.553

6.  Detection of sentinel lymph nodes in minimally invasive surgery using indocyanine green and near-infrared fluorescence imaging for uterine and cervical malignancies.

Authors:  Elizabeth L Jewell; Juan Juan Huang; Nadeem R Abu-Rustum; Ginger J Gardner; Carol L Brown; Yukio Sonoda; Richard R Barakat; Douglas A Levine; Mario M Leitao
Journal:  Gynecol Oncol       Date:  2014-02-28       Impact factor: 5.482

7.  The Advantage of Pinpoint Camera System With Indocyanine Green for Sentinel Lymph Node Micrometastasis Detection in Low Risk Endometrial Cancer.

Authors:  Alexandros Lazaridis; Stylianos Kogeorgos; Panagiotis Balinakos; Kitty Pavlakis; Theofani Gavresea; George Pistofidis
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

Review 8.  Sentinel lymph node mapping and staging in endometrial cancer: A Society of Gynecologic Oncology literature review with consensus recommendations.

Authors:  Robert W Holloway; Nadeem R Abu-Rustum; Floor J Backes; John F Boggess; Walter H Gotlieb; W Jeffrey Lowery; Emma C Rossi; Edward J Tanner; Rebecca J Wolsky
Journal:  Gynecol Oncol       Date:  2017-05-28       Impact factor: 5.482

9.  Sentinel lymph node mapping with pathologic ultrastaging: a valuable tool for assessing nodal metastasis in low-grade endometrial cancer with superficial myoinvasion.

Authors:  Christine H Kim; Fady Khoury-Collado; Emma L Barber; Robert A Soslow; Vicky Makker; Mario M Leitao; Yukio Sonoda; Kaled M Alektiar; Richard R Barakat; Nadeem R Abu-Rustum
Journal:  Gynecol Oncol       Date:  2013-10-04       Impact factor: 5.482

10.  Incidence of pelvic lymph node metastasis using modern FIGO staging and sentinel lymph node mapping with ultrastaging in surgically staged patients with endometrioid and serous endometrial carcinoma.

Authors:  Jennifer J Mueller; Silvana Pedra Nobre; Kenya Braxton; Kaled M Alektiar; Mario M Leitao; Carol Aghajanian; Lora H Ellenson; Nadeem R Abu-Rustum
Journal:  Gynecol Oncol       Date:  2020-04-01       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.